AI Article Synopsis
- Flurbiprofen axetil (FA) is a promising anti-inflammatory drug but has limitations like poor solubility and short circulation time.
- Researchers improved FA delivery by loading it into stealth lipid microspheres modified with an RGD peptide (cRGD-FA-SLM) to enhance its reliability in treating rheumatoid arthritis (RA).
- The developed platform showed effective targeting to inflamed joints, reduced inflammation and joint damage in arthritis models, and prolonged the drug's presence in the bloodstream, highlighting its potential for RA treatment.
Article Abstract
Background: Flurbiprofen axetil (FA) is a non-steroidal anti-inflammatory drug with good analgesic and anti-inflammatory effects. However, it suffers from poor solubility, short circulation time, and off-target binding profile, which significantly limit its clinical application. Here, we loaded FA into stealth lipid microspheres modified with the arginine-glycine-aspartic acid (RGD) peptide (cRGD-FA-SLM), and examined the therapeutic potential of the resulting platform for the treatment of rheumatoid arthritis (RA).
Methods: cRGD-FA-SLM was prepared by high pressure homogenization, and its toxicity and uptake by macrophages were examined using cultures of RAW264.7 cells. Hemolysis and hepatotoxicity tests were performed to assess the safety of the developed platform, while its pharmacokinetics, biodistribution, and therapeutic efficacy were investigated in a collagen-induced arthritis rat model.
Results: cRGD-FA-SLM showed homogeneous spherical morphology and efficient encapsulation of FA. The developed platform was non-toxic to normal macrophages and was selectively internalized by lipopolysaccharide-activated macrophages in vitro, while it distributed mainly to arthritic joints and significantly prolonged FA in circulation in vivo. cRGD-FA-SLM also significantly reduced the expression of prostaglandin E2 and alleviated joint edema and bone erosion, showing prolonged analgesic effects in arthritic rats.
Conclusion: cRGD-FA-SLM shows good inflammation-targeting ability and prolongs drug circulation in vivo, suggesting promise as an anti-inflammatory and analgesic agent for targeted RA treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497098 | PMC |
| http://dx.doi.org/10.2147/IJN.S419502 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of thumbtack needle acupuncture combined with PCIA on patients after laparoscopic myomectomy: a randomized controlled trial.
Front Med (Lausanne)
November 2024
Department of Gynecology and Obstetrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China.
Article Synopsis
- - The study investigates the effectiveness of thumbtack needle acupuncture (TNA) combined with patient-controlled intravenous analgesia (PCIA) to improve recovery after laparoscopic myomectomy (LM), addressing pain and gastrointestinal issues that hinder same-day discharge.
- - 52 patients were randomly assigned to receive either TNA or standard care, and various pain and recovery metrics were measured, including Visual Analog Scale (VAS) scores and gastrointestinal function.
- - Results showed that the TNA group had significantly lower pain scores, reduced need for additional pain medications, quicker gastrointestinal recovery, and shorter hospital stays compared to the control group, indicating TNA may enhance post-surgery outcomes.
Effect of 5% lidocaine-medicated plaster in preventing chronic postsurgical pain after knee replacement: protocol for a randomized double-blind placebo-controlled trial.
Front Pharmacol
October 2024
Department of Pain Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: With an aging population, knee arthroplasty is increasingly common; however, chronic postsurgical pain (CPSP) affects up to 30% of patients. This study aims to evaluate the efficacy of 5% lidocaine-medicated plaster (LP5) in preventing CPSP among patients undergoing knee arthroplasty.
Methods: This is a dual-center, randomized, double-blind, placebo-controlled trial involving 128 adult patients scheduled for knee arthroplasty.
Flurbiprofen axetil is involved in basal-like breast cancer metastasis via suppressing the MEK/ERK signaling pathway.
Cell Biol Int
January 2025
Department of Anesthesiology, Naval Medical Center, Naval Medical University, Shanghai, China.
Flurbiprofen axetil is commonly utilized in clinical practice as one of the nonsteroidal anti-inflammatory drugs (NSAIDs) and is included in multimodal analgesia regimens postbreast cancer surgery. Numerous NSAIDs have been studied for their potential to both promote and inhibit cancer. Given the variability in their effects on tumors, further investigation into the specific role of flurbiprofen axetil is warranted.
View Article and Find Full Text PDFEsketamine vs. placebo combined with erector spinae plane block vs. intercostal nerve block on quality of recovery following thoracoscopic lung resection: A randomized controlled factorial trial.
Int J Surg
August 2024
Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Background: Multimodal analgesic strategy is pivotal for enhanced recovery after surgery. The objective of this trial was to assess the effect of subanesthetic esketamine vs. placebo combined with erector spinae plane block (ESPB) vs.
View Article and Find Full Text PDFComparison of opioid-free and opioid-inclusive propofol anaesthesia for thyroid and parathyroid surgery: a randomised controlled trial.
Anaesthesia
October 2024
Department of Anaesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Article Synopsis
- Postoperative nausea and vomiting (PONV) are common and negatively impact patients after thyroid and parathyroid surgeries; the study aimed to see if opioid-free propofol anesthesia could lower these occurrences.
- A randomized trial involving 394 patients showed that those receiving opioid-free anesthesia had a significantly lower rate of PONV (5%) compared to those with opioid-inclusive anesthesia (24%).
- Other benefits of opioid-free anesthesia included fewer rescue anti-emetic needs, reduced hypotension and desaturation post-surgery, and higher patient satisfaction, while slightly delaying tracheal extubation time.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!